Alzinova Q4 report - Right on track
2023-02-23 10:24:00
Redeye provides a research update on Alzinova following the company’s Q4 report published earlier today and recent clinical progress with lead candidate ALZ-101. We make some slight adjustments to our overall estimates following a revision of our model. However, we reiterate our previous fair value range (SEK1 – SEK20) with a base case valuation of SEK10 as we continue to have a positive outlook on the case.
Read more and download the Research Update.
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/